Dec 23, 2019 / 01:30PM GMT
Operator
Good day, ladies and gentlemen, and welcome to the Sarepta Therapeutics Business Update Conference Call. (Operator Instructions) As a reminder, today's program is being recorded.
And now I'd like to introduce your host for today's program, Ian Estepan, Senior Vice President, Chief of Staff and Corporate Affairs. Please go ahead.
Ian M. Estepan - Sarepta Therapeutics, Inc. - Senior VP of Corporate Affairs & Chief of Staff
Thank you, Charl, and thank you all for joining today's call and happy holidays to all.
Earlier this morning, we issued a press release regarding a licensing agreement with Roche for rights to our micro-dystrophin gene therapy for Duchenne muscular dystrophy in territories outside the United States. The press release is available on our website at www.sarepta.com.
Joining us on the call today are Doug Ingram, Sandy Mahatme, Bo Cumbo, Dr. Gilmore O'Neill, and Dr. Louise Rodino-Klapac. After our formal remarks, we'll open the call for Q&A.
Sarepta Therapeutics Inc to Discuss Partnership with Roche Holding AG for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot